| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTXII |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | N |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTXII重组蛋白的模拟参考文献示例(内容为虚构，仅供参考)：
1. **文献名称**: "Expression and Purification of Recombinant CTXII for Cartilage Degradation Studies"
**作者**: Smith J, et al.
**摘要**: 本研究报道了通过大肠杆菌系统高效表达并纯化重组CTXII蛋白的工艺。该蛋白可用于体外模拟软骨降解过程，并作为骨关节炎生物标记物的检测标准品。
2. **文献名称**: "Development of an ELISA Kit Based on Recombinant CTXII for Osteoarthritis Diagnosis"
**作者**: Zhang L, et al.
**摘要**: 作者利用重组CTXII蛋白开发了一种高灵敏度ELISA检测方法，能够定量检测患者血清中的CTXII水平，为早期骨关节炎诊断提供了新工具。
3. **文献名称**: "Recombinant CTXII as a Therapeutic Target in Collagen-Induced Arthritis Models"
**作者**: Müller R, et al.
**摘要**: 通过在小鼠模型中注射重组CTXII蛋白，研究发现其可诱导特异性抗体产生，显著减轻关节炎症反应，提示其潜在治疗应用价值。
4. **文献名称**: "Structural Characterization of Recombinant Human CTXII Using Mass Spectrometry"
**作者**: Tanaka K, et al.
**摘要**: 采用质谱技术对重组CTXII蛋白进行结构解析，确认其翻译后修饰位点，为后续功能研究和药物开发提供了分子基础。
---
**注意**：以上文献信息为模拟示例，实际文献需通过PubMed、Web of Science等学术数据库检索。建议使用关键词"recombinant CTXII protein"或"CTX-II biomarker"进行精确查询。
CTXII (Cobra Toxin Factor II) recombinant protein is a biologically active derivative derived from the venom of cobra snakes (primarily *Naja* species). It belongs to the family of cobra venom factors (CVFs), which are known for their ability to interact with the complement system—a critical component of innate immunity. Native CTXII is a non-enzymatic protein that binds to complement component C3. triggering uncontrolled activation of the alternative complement pathway, leading to its depletion. This property has made it a valuable tool in studying complement-mediated diseases and immune regulation.
Recombinant CTXII is produced using genetic engineering techniques, often expressed in mammalian or bacterial systems to ensure proper folding and functionality. Its production involves cloning the gene encoding CTXII into expression vectors, followed by purification via chromatography. The recombinant form retains the ability to bind C3 and modulate complement activity, mimicking the effects of native cobra venom factor while avoiding the toxicity associated with crude venom.
Research applications of CTXII recombinant protein include studying complement-related pathologies (e.g., autoimmune disorders, ischemia-reperfusion injury, and neurodegenerative diseases), developing complement-targeted therapies, and exploring its anti-inflammatory properties. It is also used in preclinical models to temporarily deplete complement activity, enabling researchers to dissect the roles of the complement system in various physiological and pathological processes.
Due to its specificity and reproducibility, recombinant CTXII offers a safer, standardized alternative to native venom extracts, aligning with ethical and regulatory standards in biomedical research. Its development underscores the intersection of toxinology and therapeutic innovation, highlighting how venom-derived proteins can be repurposed for scientific and clinical advancements.
×
